Literature DB >> 18671662

Effectiveness of benzodiazepines: do they work or not?

Malcolm Lader1.   

Abstract

The benzodiazepines have been extensively prescribed for decades for vague indications such as anxiety, sleeplessness and muscle tension. Despite increasing knowledge of their adverse effects, such as sedation, psychomotor and cognitive impairment, and dependence on long-term use, and the recent advent of better alternatives, their use continues largely unabated. The paper under review assesses the sparse high-quality data related to efficacy (denoted by the dropout rate for failure to respond), effectiveness (dropout rate for any reason) and dropout for adverse effects. The conclusion is that efficacy was significantly higher for the drugs as compared with placebo; by contrast, no convincing evidence was found of any short-term effectiveness: and adverse effects were 1.5-times more frequent in the drug-treated patients. Various reasons for these results are discussed. I point out the changes in diagnostic criteria over the years and the lack of accepted methods of assessing estimates of effectiveness in clinical practice. Excessive prescribing of these controversial drugs is likely to continue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671662     DOI: 10.1586/14737175.8.8.1189

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  15 in total

1.  Comparing the discriminative stimuli produced by either the neuroactive steroid pregnanolone or the benzodiazepine midazolam in rats.

Authors:  Xiang Bai; Lisa R Gerak
Journal:  Psychopharmacology (Berl)       Date:  2010-10-23       Impact factor: 4.530

Review 2.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

3.  A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam.

Authors:  Ingunn Fride Tvete; Trine Bjørner; Tor Skomedal
Journal:  Br J Gen Pract       Date:  2016-03-10       Impact factor: 5.386

4.  Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice.

Authors:  Paolo Magnani; Anita Conforti; Elisabetta Zanolin; Marta Marzotto; Paolo Bellavite
Journal:  Psychopharmacology (Berl)       Date:  2010-04-20       Impact factor: 4.530

5.  Long-term use of benzodiazepines in older patients in Germany: a retrospective analysis.

Authors:  Louis Jacob; Michael A Rapp; Karel Kostev
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

6.  Psychiatrist decision-making towards prescribing benzodiazepines: the dilemma with substance abusers.

Authors:  Carla Beth Marienfeld; Ece Tek; Esperanza Diaz; Richard Schottenfeld; Marek Chawarski
Journal:  Psychiatr Q       Date:  2012-12

Review 7.  Insomnia: Neurophysiological and neuropsychological approaches.

Authors:  Célyne H Bastien
Journal:  Neuropsychol Rev       Date:  2011-01-20       Impact factor: 7.444

8.  Serum 3-Hydroxybutyrate in Patients with Psychogenic Somatoform Symptoms May Be a Predictor of the Effectiveness of Sertraline and Venlafaxine.

Authors:  Norihiro Saito; Masamichi Itoga; Satoko Minakawa; Hiroyuki Kayaba
Journal:  Int J Gen Med       Date:  2021-05-10

9.  Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.

Authors:  Ariel Berger; John Edelsberg; Vamsi Bollu; Jose Ma J Alvir; Ashish Dugar; Ashish V Joshi; Gerry Oster
Journal:  BMC Psychiatry       Date:  2011-12-12       Impact factor: 3.630

10.  Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.

Authors:  Ariel Berger; John Edelsberg; Michael Treglia; Jose Ma J Alvir; Gerry Oster
Journal:  BMC Psychiatry       Date:  2012-10-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.